Federica Pecci

ORCID: 0009-0000-9289-2007

Also affiliated with Dana-Farber Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer”.

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.07.005

N/A

0.701DataRank · unranked

106 citations

Joao V. Alessi, Arielle Elkrief, Xinan Wang, Alessio Cortellini, Y Y Li +27 more

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1207

N/A

0.542DataRank · unranked

36 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Hira Rizvi, Arielle Elkrief +23 more

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Nature Communications(2023)10.1038/s41467-023-39874-8

N/A

0.515DataRank · unranked

30 citations

Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti +13 more

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-006994

N/A

0.416DataRank · unranked

15 citations

Joao V. Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1735

N/A

0.345DataRank · unranked

9 citations

Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo +26 more

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007618

N/A

0.330DataRank · unranked

8 citations

Adam Price, Allison L. Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief +14 more

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

Nature Communications(2025)10.1038/s41467-025-61823-w

N/A

0.312DataRank · unranked

7 citations

Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Daniel Boiarsky +32 more

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2990

N/A

0.312DataRank · unranked

7 citations

Rohit Thummalapalli, Stephanie Alden, Biagio Ricciuti, Joao V. Alessi, Arielle Elkrief +18 more

Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer

Human Genetics and Genomics Advances(2024)10.1016/j.xhgg.2024.100320

N/A

0.269DataRank · unranked

5 citations

Kangcheng Hou, Biagio Ricciuti, Joao V. Alessi, Xihao Li, Federica Pecci +8 more

Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012205

N/A

0DataRank · unranked

1 citations

Biagio Ricciuti, Arielle Elkrief, Joao V Alessi, Alessandro Di Federico, Federica Pecci +11 more

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Drugs in Context(2022)10.7573/dic.2022-7-4

N/A

0DataRank · unranked

13 citations

Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci +6 more

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancers

Research Square(2022)10.21203/rs.3.rs-2273813/v1

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Xinan Wang, Giuseppe Lamberti, Arielle Elkrief, Federica Pecci +12 more

Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study

medRxiv(2022)10.1101/2022.12.05.22283131

N/A

0DataRank · unranked

0 citations

Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul +16 more

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO Precision Oncology(2023)10.1200/po.23.00295

N/A

0DataRank · unranked

5 citations

Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh +16 more

Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9107

N/A

0DataRank · unranked

0 citations

Biagio Ricciuti, Chaitanya Bandlamudi, Daniel M. Muldoon, Jia Luo, Joao Victor Machado Alessi +13 more

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.03.045

N/A

0DataRank · unranked

5 citations

Federica Pecci, Biagio Ricciuti, Felix H. Gottlieb, Francesco Facchinetti, Guilherme Harada +21 more